Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 7/20 | 0.48 |
| ▸ | ACACA | Q13085 | 5/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13759315 | 1.00 | GPR139 (0.49) | GPR139HSD17B10ACACBACACAKCNA5 | |
| SCHEMBL12341889 | 1.00 | GPR139 (0.49) | GPR139HSD17B10ACACBACACAKCNA5 | |
| SCHEMBL13759318 | 1.00 | GPR139 (0.49) | GPR139HSD17B10ACACBACACAKCNA5 | |
| SCHEMBL23961320 | 0.89 | MMP9 (0.49) | GPR139HSD17B10ACACBACACAKCNA5 | |
| SCHEMBL23961371 | 0.83 | GPR139 (0.64) | GPR139 | |
| SCHEMBL13452335 | 0.82 | ALDH1A1 (0.49) | HSD17B10ACACBACACAALDH1A1MAPKAPK2 | |
| SCHEMBL12341890 | 0.81 | ALDH1A1 (0.59) | ACACBACACAALDH1A1 | |
| SCHEMBL12184906 | 0.81 | ALDH1A1 (0.50) | ACACBACACAALDH1A1MAPKAPK2 | |
| SCHEMBL13348738 | 0.81 | ACACB (0.47) | ACACBACACAALDH1A1 | |
| SCHEMBL3893098 | 0.81 | ALDH1A1 (0.59) | ACACBACACAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-6399787-B1 | TRANSITION METAL COMPLEX | PENN STATE RESEARCH FOUNDATION | 2002-06-04 | — | — | US | disclosed |
| WO-1999059721-A1 | CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | GPR139 1852/4885HSD17B10 612/4885ACACB 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.